Piper Sandler Downgrades Ardelyx(ARDX.US) to Hold Rating, Cuts Target Price to $7
Piper Sandler Sticks to Their Hold Rating for Ardelyx (ARDX)
Ardelyx Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $10 Price Target
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $10
Wedbush Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $11
Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
Ardelyx (ARDX.US) sues USA CMS to oppose the bundling of payment system for Xphozah, a drug for kidney disease, into medical insurance.
Pharmaceutical company Ardelyx announced that it has filed lawsuits against the US Department of Health and Human Services and the Centers for Medicare & Medicaid Services (CMS) for medical insurance and medical subsidy services.
Citi Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $10
Ardelyx's Strategic Response to Regulatory Challenges: A High-Risk Buy Rating With Potential for Substantial Return
Recent 29% Pullback Isn't Enough to Hurt Long-term Ardelyx (NASDAQ:ARDX) Shareholders, They're Still up 108% Over 5 Years
Ladenburg Thalmann Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $12.5
Ardelyx Is Maintained at Buy by Citigroup
Ardelyx Analyst Ratings
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $12
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $10
Express News | Ardelyx, Inc. : H.c. Wainwright Cuts Target Price to $10 From $13
Citi Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $10
Ardelyx's Tumble Seen as Opportunity To Buy Dip -- Market Talk
No Data